In addition, DNase, a commonly used NETs inhibitor, has been successfully applied in the treatment of Alzheimer’s disease, and genetic variants in DNase genes including DNASE1, DNASE2 and DNASE1L3 can result in the downregulation of DNase expression in Alzheimer’s disease (Kretzschmar et al., 2021; Tetz & Tetz, 2016). This evidence concerns the gene SPINK5 and early-onset autosomal dominant Alzheimer disease.